LEXICON PHARMACEUTICALS, INC. Deferred Tax Asset, Interest Carryforward
LEXICON PHARMACEUTICALS, INC. (LXRX) had Deferred Tax Asset, Interest Carryforward of $2.08 million as of 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetInterestCarryforward · last filed 2026-03-05
- 2025-12-31: Deferred Tax Asset, Interest Carryforward $2.08M.
- 2024-12-31: Deferred Tax Asset, Interest Carryforward $1.75M.
- 2023-12-31: Deferred Tax Asset, Interest Carryforward $1.36M.
- 2022-12-31: Deferred Tax Asset, Interest Carryforward $398.00K.
| Period end | Deferred Tax Asset, Interest Carryforward |
|---|---|
| 2025-12-31 | $2.08M 10-K · filed 2026-03-05 |
| 2024-12-31 | $1.75M 10-K · filed 2026-03-05 |
| 2023-12-31 | $1.36M 10-K · filed 2025-03-07 |
| 2022-12-31 | $398.00K 10-K · filed 2024-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |